Hot Topics in Myeloma

Recent developments in multiple myeloma include the FDA approval of linvoseltamab, a bispecific antibody targeting BCMA with a 70% response rate in heavily pretreated patients. Ongoing debate surrounds belantamab mafodotin, an antibody-drug conjugate with promising efficacy but notable ocular toxicity, currently under FDA review despite approval abroad. Minimal residual disease (MRD) testing is gaining prominence as a decision-making tool, with trials like MIDAS evaluating MRD status to guide treatment intensity. Long-term follow-up from the CARTITUDE-1 trial revealed that one-third of patients receiving cilta-cel remained disease-free at five years, raising critical discussions on how to define cure in multiple myeloma. Collectively, these developments highlight significant progress toward durable remission and potential pathways to cure.

Patient Empowerment: Shared Decision Making

Shared decision-making in multiple myeloma care emphasizes patient empowerment, active participation, and alignment of treatment decisions with personal values and preferences. The model involves structured discussions where healthcare providers present evidence-based treatment options, assess patient goals, and evaluate practical considerations such as treatment setting, cost, and quality of life. Patients are encouraged to remain informed through educational resources, clinical trial opportunities, and supportive care networks, while also leveraging tools like journals, telehealth, and after-visit summaries. The approach highlights that decision-making is iterative, allowing for reevaluation over time, and can significantly improve adherence, satisfaction, and long-term outcomes.

VIEW SLIDES

Myeloma 101: The Big Picture Perspective with Q&A

Multiple myeloma (MM) is a type of blood cancer that originates in plasma cells, which are found in the bone marrow and play a role in producing antibodies. ​ MM disrupts normal bone marrow function, leading to complications such as anemia, bone damage, kidney dysfunction, and weakened immunity. The disease progresses through stages, including MGUS (Monoclonal Gammopathy of Undetermined Significance), smoldering myeloma, and active myeloma, each with distinct characteristics and risks of progression.

View the Slides

Navigating Insurance and Medical Bills

Triage Cancer is a nonprofit organization offering free education and resources to individuals diagnosed with cancer, their caregivers, and healthcare professionals. It provides guidance on legal, financial, and practical issues, including health insurance, medical bills, employment, disability insurance, estate planning, and more.

View the Slides

Emotional and Physical Wellbeing

Exercise plays a vital role in improving the quality of life for individuals with multiple myeloma. ​ It offers numerous benefits, including enhanced muscle strength, mobility, endurance, neuropathy relief, improved activities of daily living (ADLs), immune system support, reduced fatigue, pain management, better body composition, and improved bone health.

View the Slides

Partnering with the IMF

Sylvia Dsouza, Vice President of Development at the International Myeloma Foundation (IMF), highlights the importance of community partnerships, philanthropy, and volunteer engagement in advancing IMF’s mission. She emphasizes how patients, caregivers, and supporters can contribute through peer-to-peer fundraising, recurring donations, major gifts, planned giving, and advocacy initiatives. Examples include Miracles for Myeloma 5K events, grassroots advocacy efforts, and the Medical Health Equity Scholar Program, which trains physicians to recognize myeloma earlier. Through these collective efforts, the IMF has expanded its global reach, strengthened its support networks, and invested significantly in research, education, and patient empowerment.

View the Slides